Mesoblast Ltd (nasdaq:MESO) Share Price

Company Profile

Business description
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUS
T: +61 396396036
E: [email protected]
https://www.mesoblast.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
108

Recommended

Discounted exit raises investor concerns.

Yingqi Tan, CFA | 21 September 2026

The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.

Jacob Robbins | 21 September 2026

Morningstar analysts’ take on the takeover for this undervalued industrial player.

Esther Holloway | 20 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,919.10	3.60	-0.04%
CAC 40	8,142.08	77.06	0.96%
DAX 40	25,573.66	269.60	1.07%
Dow JONES (US)	51,886.95	204.31	0.40%
FTSE 100	10,737.18	78.05	0.73%
HKSE	25,042.71	291.93	1.18%
NASDAQ	26,951.40	428.86	1.62%
Nikkei 225	65,018.95	882.70	1.38%
NZX 50 Index	13,821.20	82.06	0.60%
S&P 500	7,729.11	78.61	1.03%
S&P/ASX 200	8,731.90	0.70	0.01%
SSE Composite Index	3,949.91	38.04	0.97%